Analysts Anticipate Adaptimmune Therapeutics PLC – (ADAP) to Announce -$0.27 EPS

Equities research analysts predict that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will announce earnings of ($0.27) per share for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Adaptimmune Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.35) and the highest estimate coming in at ($0.18). Adaptimmune Therapeutics reported earnings per share of ($0.29) during the same quarter last year, which suggests a positive year-over-year growth rate of 6.9%. The company is scheduled to report its next quarterly earnings report on Thursday, March 21st.

According to Zacks, analysts expect that Adaptimmune Therapeutics will report full-year earnings of ($0.98) per share for the current financial year, with EPS estimates ranging from ($1.21) to ($0.84). For the next year, analysts expect that the business will post earnings of ($1.24) per share, with EPS estimates ranging from ($1.50) to ($0.94). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow Adaptimmune Therapeutics.

Adaptimmune Therapeutics (NASDAQ:ADAP) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.09. Adaptimmune Therapeutics had a negative net margin of 139.57% and a negative return on equity of 46.63%. The business had revenue of $40.79 million during the quarter, compared to analyst estimates of $29.41 million.

ADAP has been the subject of several research analyst reports. BidaskClub downgraded Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday. Zacks Investment Research downgraded Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday. ValuEngine lowered Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday. Cowen reiterated a “buy” rating on shares of Adaptimmune Therapeutics in a research note on Tuesday. Finally, Raymond James cut their target price on Adaptimmune Therapeutics from $20.00 to $16.00 and set a “buy” rating on the stock in a research note on Monday, October 22nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $15.44.

In other Adaptimmune Therapeutics news, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of the company’s stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $10.25, for a total value of $256,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Enterprise Associates 14 New purchased 3,000,000 shares of the stock in a transaction dated Friday, September 7th. The shares were acquired at an average price of $1.67 per share, with a total value of $5,010,000.00. The disclosure for this purchase can be found here. Corporate insiders own 26.47% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of ADAP. Baillie Gifford & Co. raised its position in Adaptimmune Therapeutics by 18.2% in the 2nd quarter. Baillie Gifford & Co. now owns 3,033,261 shares of the biotechnology company’s stock valued at $36,005,000 after purchasing an additional 467,852 shares in the last quarter. BlackRock Inc. grew its stake in Adaptimmune Therapeutics by 2.5% during the 1st quarter. BlackRock Inc. now owns 806,952 shares of the biotechnology company’s stock worth $9,062,000 after buying an additional 19,765 shares during the last quarter. Frontier Capital Management Co. LLC grew its stake in Adaptimmune Therapeutics by 351.1% during the 3rd quarter. Frontier Capital Management Co. LLC now owns 698,694 shares of the biotechnology company’s stock worth $9,474,000 after buying an additional 543,809 shares during the last quarter. Stanley Laman Group Ltd. purchased a new position in Adaptimmune Therapeutics during the 3rd quarter worth approximately $7,665,000. Finally, JPMorgan Chase & Co. grew its stake in Adaptimmune Therapeutics by 786.0% during the 1st quarter. JPMorgan Chase & Co. now owns 185,660 shares of the biotechnology company’s stock worth $2,085,000 after buying an additional 164,704 shares during the last quarter. 58.99% of the stock is currently owned by hedge funds and other institutional investors.

Shares of ADAP stock traded down $0.48 on Friday, reaching $6.18. The company’s stock had a trading volume of 682,729 shares, compared to its average volume of 523,246. The firm has a market cap of $616.54 million, a PE ratio of -7.73 and a beta of 2.02. Adaptimmune Therapeutics has a 1 year low of $5.73 and a 1 year high of $14.63.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Featured Story: What Is An Exchange-Traded Fund (ETF)?

Get a free copy of the Zacks research report on Adaptimmune Therapeutics (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply